PolyTherics extends deal with Celtic Pharma
This article was originally published in Scrip
Executive Summary
PolyTherics has granted Celtic Pharma an exclusive licence to develop and commercialise the first novel biotherapeutic discovered under the two companies' existing collaboration. Celtic Pharma is a private equity investment company focused on biopharmaceuticals.
PolyTherics will receive an upfront licence fee from Celtic as well as regulatory milestones and royalties on product sales. The product candidate should enter clinical trials in the next one to two years, PolyTherics's CEO Dr Keith Powell told Scrip.